 Renal Insufficiency, Chronic
"Renal Insufficiency, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Descriptor ID |
D051436
|
| MeSH Number(s) |
C12.777.419.780.750 C13.351.968.419.780.750
|
| Concept/Terms |
Renal Insufficiency, Chronic- Renal Insufficiency, Chronic
- Chronic Renal Insufficiencies
- Renal Insufficiencies, Chronic
- Chronic Renal Insufficiency
- Chronic Kidney Insufficiency
- Kidney Insufficiency, Chronic
- Chronic Kidney Insufficiencies
- Kidney Insufficiencies, Chronic
|
Below are MeSH descriptors whose meaning is more general than "Renal Insufficiency, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Renal Insufficiency, Chronic".
This graph shows the total number of publications written about "Renal Insufficiency, Chronic" by people in this website by year, and whether "Renal Insufficiency, Chronic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 0 | 2 | | 2008 | 3 | 0 | 3 | | 2009 | 3 | 1 | 4 | | 2010 | 7 | 2 | 9 | | 2011 | 6 | 0 | 6 | | 2012 | 8 | 4 | 12 | | 2013 | 21 | 3 | 24 | | 2014 | 19 | 5 | 24 | | 2015 | 21 | 3 | 24 | | 2016 | 12 | 1 | 13 | | 2017 | 19 | 6 | 25 | | 2018 | 15 | 3 | 18 | | 2019 | 21 | 1 | 22 | | 2020 | 23 | 4 | 27 | | 2021 | 24 | 3 | 27 | | 2022 | 8 | 0 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Renal Insufficiency, Chronic" by people in Profiles.
-
Khan MS, Bakris GL, Packer M, Shahid I, Anker SD, Fonarow GC, Wanner C, Weir MR, Zannad F, Butler J. Kidney function assessment and endpoint ascertainment in clinical trials. Eur Heart J. 2022 04 06; 43(14):1379-1400.
-
Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022 04 01; 45(4):888-897.
-
Wang K, Luo Z, Li C, Pinto JM, Shiroma EJ, Simonsick EM, Chen H. Olfaction and kidney function in community-dwelling older adults. PLoS One. 2022; 17(2):e0264448.
-
Eadon MT, Maddatu J, Moe SM, Sinha AD, Ferreira RM, Miller BW, Sher SJ, Su J, Pratt VM, Chapman AB, Skaar TC, Moorthi RN. Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360. 2022 Feb; 3(2):307-316.
-
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10; 43(6):474-484.
-
Charytan DM, Yu J, Jardine MJ, Cannon CP, Agarwal R, Bakris G, Greene T, Levin A, Pollock C, Powe NR, Arnott C, Mahaffey KW. Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022 03; 17(3):361-373.
-
Stavas J, Gerber D, Coca SG, Silva AL, Johns A, Jain D, Bertram T, Díaz-González de Ferris M, Bakris G. Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58.
-
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S175-S184.
-
Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Górriz JL, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021 12 21; 42(48):4891-4901.
-
Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|